ALX Oncology Holdings (ALXO)
(Real Time Quote from BATS)
$14.08 USD
+0.46 (3.38%)
Updated May 22, 2024 11:08 AM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ALXO 14.08 +0.46(3.38%)
Will ALXO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALXO
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
Other News for ALXO
Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)
Piper Sandler Sticks to Its Buy Rating for ALX Oncology Holdings (ALXO)
ALX Oncology price target raised by $5 at H.C. Wainwright, here's why